Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road Database
News for Outlets

China's Fosun Pharma (600196.SH) H1 net profit up 44.8pct on yr

August 25, 2021


Abstract : Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196.SH, 02196.HK), China's leading innovation-driven international healthcare group, reported 2.482 billion yuan of net profit in the first half of 2021, representing a year-on-year growth of 44.77 percent.

139696697_16115805357091n.jpg

Medical workers are on duty at a COVID-19 nucleic acid testing station in Yuen Long, Hong Kong, south China, Jan. 23, 2021. (Xinhua/Lo Ping Fai)

BEIJING, Aug. 25 (Xinhua) -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196.SH, 02196.HK), China's leading innovation-driven international healthcare group, reported 2.482 billion yuan of net profit in the first half of 2021, representing a year-on-year growth of 44.77 percent.

Its operating revenue reached 16.952 billion yuan, increasing by 20.85 percent year on year, with revenue in regions outside Chinese mainland and other countries accounting for 30.66 percent of the total, according to the company's interim report available on Monday. 

Research and development investment rose by 29.73 percent year on year to 1.562 billion yuan,  the interim results show.

In the first half, the company also made progress in cooperation with BioNTech SE, a German-based mRNA vaccine maker. Fosun Pharma supplied some 4.4 million doses of BNT162b2, a mRNA Covid-19 vaccine, to China's two SARs, Hong Kong and Macao, in the first half of 2021. In July, buyers in Taiwan, a province of China, purchased some 15 million doses of BNT162b2 to help the local government's fight against COVID-19 outbreak. 

(Edited by Tian Shenyoujia with Xinhua Silk Road, tianshenyoga0524@163.com)

Scan the QR code and push it to your mobile phone

Keyword: net profit vaccine Fosun Pharma

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial